NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

March 31, 2016

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Axitinib

Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.

Trial Locations (3)

University of Pennsylvania, Abramson Cancer Center, Philadelphia

Cleveland Clinic, Taussig Cancer Institute, Cleveland

Missouri Valley Cancer Consortium, Omaha